Top Section/Ad
Top Section/Ad
Most recent
A junior banker respects their MD, but cannot live with his disorganisation. Can things ever improve?
This year’s expected surge in IPOs and M&A deals should drive a proliferation of strategic equity derivative transactions, with $2bn of fees up for grabs
This week a managing director deals with the awkwardness of their boss finding out they had been in contention for a job at another firm
More articles/Ad
More articles/Ad
More articles
-
The China Securities Regulatory Commission (CSRC) has shed some light on the kinds of companies that are eligible to list on the Star board, solving part of a problem that has long puzzled potential IPO candidates. -
The biggest investment banks are enjoying strong trading revenues from the market moves related to the coronavirus pandemic, alleviating a freeze in M&A and underwriting activity. The banks appear well-placed to deal with corporate drawdowns, although there is some debate around wider liquidity profiles.
-
Firms across Europe are clamouring for crisis funding but while debt advisory bankers have joined the frontline in finding solutions some admit they may struggle to cope with the sheer scale of the challenge, writes David Rothnie.
-
Bankers in Paris are adjusting to a new life of lockdown following president Emmanuel Macron’s declaration of war against Covid-19 on Monday, which has led to the toughest restrictions being imposed on daily life in France since the Second World War.
-
Prominent short sellers have criticised European financial regulators’ clampdown on short selling as being counterproductive. Meanwhile, US hedge fund Bridgewater Associates has been unwinding its multibillion short positions in European stocks, after price falls across indices on the continent in recent days.
-
Shanghai Titan Scientific, Speechocean and Easton Biopharmaceuticals are all planning to make a second attempt at listing on Shanghai’s Star market.
